orthopedic regenerative medicine

Quick Summary New 2026 Phase 2 data for BRTX-100 (autologous mesenchymal stem cell therapy for chronic lumbar disc disease) shows sustained pain and functional improvements at 52 weeks: 56% of evaluable patients had ≥50% VAS pain reduction, 64% had ≥50% ODI disability improvement. Safety data reported no dose-limiting toxicities or